BioXcel Therapeutics (BTAI) director granted 17,000 stock options at $2.01

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. reported a new stock option grant to director Sandeep Laumas. On 01/09/2026, he received a stock option for 17,000 shares of common stock at an exercise price of $2.01 per share, expiring on 01/09/2036. The option was granted at no cost to him and is reported as directly owned, with 17,000 derivative securities beneficially owned after the transaction.

The option will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided he continues to serve as a non-employee director through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Laumas Sandeep

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laumas Sandeep

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.01	01/09/2026		A		17,000		(1)	01/09/2036	Common Stock	17,000	$0	17,000	D

Explanation of Responses:

1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

	/s/ Richard Steinhart, Attorney-in-Fact for Sandeep Laumas	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did BioXcel Therapeutics (BTAI) disclose in this Form 4?

The filing shows that non-employee director Sandeep Laumas was granted a stock option for 17,000 shares of BioXcel Therapeutics, Inc. common stock on 01/09/2026.

How many BioXcel Therapeutics (BTAI) options were granted to Sandeep Laumas and at what price?

Sandeep Laumas received a stock option (right to buy) for 17,000 shares of common stock with an exercise price of $2.01 per share.

When do the new BioXcel Therapeutics (BTAI) stock options granted to Sandeep Laumas vest?

The option vests on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual stockholders' meeting after the grant date, if he continues serving as a non-employee director through that date.

What is the expiration date of the BioXcel Therapeutics (BTAI) options reported in this Form 4?

The stock option granted to Sandeep Laumas expires on 01/09/2036, as disclosed in the derivative securities table.

Did Sandeep Laumas buy or sell any BioXcel Therapeutics (BTAI) common shares in this filing?

No common stock purchases or sales are reported. The Form 4 only reports the grant of a stock option for 17,000 underlying shares.

How many BioXcel Therapeutics (BTAI) derivative securities does Sandeep Laumas own after this transaction?

After the reported grant, the filing lists 17,000 derivative securities (stock options) beneficially owned, reported as direct ownership.

Is the stock option grant to Sandeep Laumas a routine director compensation event for BioXcel Therapeutics (BTAI)?

The filing describes an option grant to a non-employee director with time- and service-based vesting, which is consistent with typical equity-based director compensation structures.